These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 17564101

  • 1. [Results of modified M-VAC chemotherapy for advanced urothelial carcinoma].
    Miura N, Numata K, Azuma K, Hashine K, Sumiyoshi Y.
    Nihon Hinyokika Gakkai Zasshi; 2007 May; 98(4):589-94. PubMed ID: 17564101
    [Abstract] [Full Text] [Related]

  • 2. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S, Matsuzaki M, Morikawa H, Nakano M, Komatsu H.
    Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
    [Abstract] [Full Text] [Related]

  • 3. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA.
    J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
    [Abstract] [Full Text] [Related]

  • 4. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N, Akaza H, Shimazui T, Ohtani M, Koiso K.
    Cancer Chemother Pharmacol; 1994 Jul; 35 Suppl():S5-8. PubMed ID: 7527735
    [Abstract] [Full Text] [Related]

  • 5. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH.
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [Abstract] [Full Text] [Related]

  • 6. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H, Okamura K, Takashi M, Shimoji T, Miyake K.
    Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.
    Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851
    [Abstract] [Full Text] [Related]

  • 10. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF.
    J Clin Oncol; 1997 Jun 15; 15(6):2449-55. PubMed ID: 9196161
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM, McCaffrey JA, Mazumdar M, Scher H, Vlamis V, Higgins G, Herr H, Bajorin DF.
    Cancer; 1999 Mar 01; 85(5):1145-50. PubMed ID: 10091800
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
    Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T.
    Jpn J Clin Oncol; 1998 Aug 01; 28(8):497-501. PubMed ID: 9769784
    [Abstract] [Full Text] [Related]

  • 13. [M-VAC chemotherapy for patients with lymph node metastases and/or locally advanced bladder carcinoma].
    Igawa M, Ueki T, Ueda M, Okada K, Usui T, Ohnishi Y, Nakatsu H, Kume T, Kodama M, Masu C.
    Hinyokika Kiyo; 1989 Aug 01; 35(8):1323-7. PubMed ID: 2683648
    [Abstract] [Full Text] [Related]

  • 14. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S, Nakano M, Matsuzaki M, Watanabe J, Morikawa H, Murata H, Oda H, Komatsu H.
    Hinyokika Kiyo; 2005 Mar 01; 51(3):155-8. PubMed ID: 15852667
    [Abstract] [Full Text] [Related]

  • 15. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N.
    Cancer; 1989 Dec 15; 64(12):2448-58. PubMed ID: 2819654
    [Abstract] [Full Text] [Related]

  • 16. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
    Kobayashi H, Obata K.
    Cancer Chemother Pharmacol; 1994 Dec 15; 35 Suppl():S14-7. PubMed ID: 7994781
    [Abstract] [Full Text] [Related]

  • 17. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
    Bellmunt Molins J, Ribas A, Albanell J, Lorente Garín JA, de Torres Mateos JA, Morote Robles J, López Palacios MA, Banús Gassol JM, Casado Cobo S, Eres N, Solé Calvo LA.
    Arch Esp Urol; 1996 Jun 15; 49(5):465-72. PubMed ID: 8766083
    [Abstract] [Full Text] [Related]

  • 18. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D, Chevret S, Rolland F, Gravis G, Geoffrois L, Roubaud G, Terrisse S, Boyle H, Chevreau C, Dauba J, Moriceau G, Alexandre I, Deplanque G, Chapelle A, Vauleon E, Colau A, Audenet F, Grellety T, Culine S.
    Eur J Cancer; 2016 Feb 15; 54():69-74. PubMed ID: 26724422
    [Abstract] [Full Text] [Related]

  • 19. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC.
    J Urol; 1985 Mar 15; 133(3):403-7. PubMed ID: 4038749
    [Abstract] [Full Text] [Related]

  • 20. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
    Igawa M, Kadena H, Ohkuchi T, Ueda M, Usui T.
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct 15; 82(10):1627-36. PubMed ID: 1770701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.